Patents Examined by R. Joynes
-
Patent number: 6376578Abstract: The invention comprises an aqueous solution comprising a water-soluble, polyamidoamine- epichlorohydrin resin, said solution having a reduced halogen content and effective wet strength agent properties, obtained by subjecting an aqueous solution comprising a water-soluble polyamido-amine-epichlorohydrin resin to an organic halogen content reducing after-treatment wherein the total halogen content is below 1% by weight, calculated on solid resin and the halogen content is below 0.1% by weight.Type: GrantFiled: November 6, 1995Date of Patent: April 23, 2002Assignee: Akzo Nobel NVInventors: Marek Gorzynski, Andreas Pingel
-
Patent number: 6358060Abstract: A two-stage medicine delivery system provides an initial dose of medicine and a second dose of medicine. The initial second doses are capable of achieving a rapid pharmacological effect and a prolonged pharmacological effect, respectively. The two-stage medicine delivery system preferably delivers a craving reduction substance, in which case, the rapid and prolonged pharmacological effects include a rapid and prolonged craving reduction. Preferably, the delivery system is a nicotine delivery system which is provided in chewing gum form or lozenge form and which provides the nicotine in a transmucosally absorbable form. The two-stage medicine delivery system preferably releases a buffering agent which increases a pH level in a user's mouth to facilitate absorption of the medicine when the delivery system is placed in the user's mouth. A method of making the medicine delivery system also is provided. The system and apparatus can be adapted to reduce cravings for alcohol, food, drugs (e.g.Type: GrantFiled: September 3, 1998Date of Patent: March 19, 2002Assignee: JSR LLCInventors: John M. Pinney, Jack E. Henningfield, Saul Shiffman, Joseph Gitchell, Edward J. Cone
-
Patent number: 6326020Abstract: Combinations of naturally occurring site 1 sodium channel blockers, such as tetrodotoxin (TTX), saxitoxin (STX), decarbamoyl saxitoxin, and neosaxitoxin (referred to jointly herein as “toxins”), with other agents, have been developed to give long duration block with improved features, including safety and specificity. In one embodiment, duration of block is greatly prolonged by combining a toxin with a local anesthetic, vasoconstrictor, glucocorticoid, and/or adrenergic drugs, both alpha agonists (epinephrine, phenylephrine), beta-blockers (propranalol), and mixed central-peripheral alpha-2 agonists (clonidine), or other agents. In another embodiment, the duration of nerve block from toxin can be greatly enhanced by the inclusion of amphiphilic or lipophilic solvents. In still another embodiment, the effectiveness of these compositions is enhanced by microencapsulation within polymeric carriers, preferably biodegradable synthetic polymeric carriers.Type: GrantFiled: May 15, 1998Date of Patent: December 4, 2001Assignees: Children's Medical Center Corporation, Brigham and Women's HospitalInventors: Daniel S. Kohane, Charles B. Berde, Gary Strichartz, Robert S. Langer
-
Patent number: 6309668Abstract: This invention relates to an abuse resistant tablet containing two or more layers having one or more drugs and one or more gelling agents and its preparation. The drug(s) and gelling agent(s) are in separate layers of the tablet. The multilayer tablet is particularly suitable for the administration of drugs prone to abuse by unauthorized parenteral administration such as analgesics, hypnotics, and anxiolytics.Type: GrantFiled: July 30, 1996Date of Patent: October 30, 2001Assignee: Aventis Pharma LimitedInventors: Richard James Bastin, Bruce Hamilton Lithgow
-
Patent number: 6284277Abstract: The subject of the invention is a freeze-dried formulation consisting of an amorphous phase and a crystalline phase, which is pharmaceutically acceptable, comprising at least one nonprotein active ingredient, characterized in that it contains mannitol and alanine in a ratio R of between 0.1 and 1, R representing the mass of mannitol to the mass of alanine.Type: GrantFiled: December 9, 1998Date of Patent: September 4, 2001Assignee: Sanofi-SynthelaboInventors: Colette Bouloumie, Thierry Breul, Laurence Colliere, Philippe Faure
-
Patent number: 6261583Abstract: The invention provides an implant composition for sustained delivery of a biologically active agent. The implant composition includes a biologically active agent, a thermoplastic polymer, an organic liquid and a small amount of an aqueous medium. The thermoplastic polymer is insoluble in water so that the implant composition has the form of a substantially homogeneous pliable, moldable solid.Type: GrantFiled: July 28, 1998Date of Patent: July 17, 2001Assignee: Atrix Laboratories, Inc.Inventors: Richard L. Dunn, Bhagya L. Chandrashekar, Kathleen A. McEnery
-
Patent number: 6235266Abstract: A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I): wherein n is from 1 to 6; X is —OH or —SH; A and B are each independently selected from the group consisting of: wherein R is H or Br; or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.Type: GrantFiled: April 30, 1999Date of Patent: May 22, 2001Assignee: The University of North Carolina at Chapel HillInventors: Monroe Jackson Stutts, III, Richard C. Boucher, Jr., Eduardo R. Lazarowski, Cara A. Geary